Genmab A/S (NASDAQ:GMAB) Raised to "Strong-Buy" at Truist Financial

Key Points

• Truist upgraded Genmab to a "Strong-Buy", and while analyst sentiment ranges from Hold to Strong Buy the consensus is a Moderate Buy with a $39.36 average price target versus Monday's open of $26.64.
• Genmab posted an earnings surprise to the downside—EPS $0.05 vs. $0.46 expected—even as revenue met estimates at $1.06B; analysts still forecast ~1.18 EPS for the current fiscal year and the company reported a 25.9% net margin.

Genmab A/S (NASDAQ:GMAB - Get Free Report) was upgraded by analysts at Truist Financial to a "strong-buy" rating in a note issued to investors on Monday,Zacks.com reports.

A number of other analysts also recently issued reports on GMAB. Morgan Stanley initiated coverage on Genmab A/S in a research note on Monday, February 16th. They issued an "equal weight" rating and a $34.00 price objective on the stock. BNP Paribas Exane raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Wednesday, April 22nd. Jefferies Financial Group assumed coverage on shares of Genmab A/S in a research report on Tuesday, February 17th. They issued a "buy" rating and a $41.50 price target on the stock. Wolfe Research assumed coverage on shares of Genmab A/S in a research note on Friday, March 27th. They set an "outperform" rating and a $32.00 price target on the stock. Finally, HC Wainwright increased their price objective on shares of Genmab A/S from $39.00 to $40.00 and gave the company a "buy" rating in a research report on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $39.36.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB opened at $26.64 on Monday. The company has a market cap of $17.12 billion, a P/E ratio of 17.19, a P/E/G ratio of 1.21 and a beta of 0.97. Genmab A/S has a 52-week low of $18.89 and a 52-week high of $35.43. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. The firm's fifty day moving average is $27.60 and its two-hundred day moving average is $30.15.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Wednesday, February 18th. The company reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.46 by ($0.41). The firm had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.06 billion. Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. As a group, analysts anticipate that Genmab A/S will post 1.18 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC lifted its holdings in shares of Genmab A/S by 291.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company's stock worth $25,000 after acquiring an additional 616 shares during the last quarter. NewEdge Advisors LLC grew its holdings in Genmab A/S by 1,229.0% during the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company's stock valued at $38,000 after purchasing an additional 1,143 shares during the last quarter. V Square Quantitative Management LLC purchased a new stake in Genmab A/S in the 1st quarter worth about $34,000. Brown Brothers Harriman & Co. lifted its stake in Genmab A/S by 143.4% in the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company's stock worth $41,000 after purchasing an additional 780 shares during the last quarter. Finally, Founders Capital Management lifted its stake in Genmab A/S by 40.0% in the fourth quarter. Founders Capital Management now owns 1,400 shares of the company's stock worth $43,000 after purchasing an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company's work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab's portfolio includes products developed in collaboration with leading global pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.